ImmunoGen
Immunogen Files FDA Application for Full Elahere Ovarian Cancer Approval
The firm submitted an application to convert its accelerated approval into full approval for its antibody-drug conjugate in FRα-positive ovarian cancer.
The firm submitted an application to convert its accelerated approval into full approval for its antibody-drug conjugate in FRα-positive ovarian cancer.